Table 5.
Univariable analysis of clinical, pathological and treatment characteristics of 188 matched patients with endometrial cancer according to DFS and OS.
| Characteristic | Patient at risk | Disease free survival | Overall survival | ||||
|---|---|---|---|---|---|---|---|
| N° events | HR (95% CI) | p value | N° events | HR (95% CI) | p value | ||
| Age | 188 | 31 | 0.93 (0.83-1.04) | 0.204 | 35 | 0.96 (0.87-1.05) | 0.391 |
| Age class | |||||||
| 70-74 years | 105 | 20 | 1.00 | 20 | 1.00 | ||
| 75-79 years | 66 | 8 | 0.64 (0.28-1.46) | 0.289 | 14 | 0.99 (0.49-2.02) | 0.986 |
| 80-84 years | 14 | 1 | 0.31 (0.04-2.29) | 0.249 | 0 | 1.00 (empty class) | – |
| 85+ years | 3 | 2 | 3.3 (0.77-14.15) | 0.107 | 1 | 1.12 (0.15-8.55) | 0.909 |
| BMI | 188 | 31 | 1.02 (0.96-1.08) | 0.498 | 35 | 1 (0.95-1.06) | 0.942 |
| Comorbidities | |||||||
| 0 | 24 | 1.00 | 5 | 1.00 | |||
| 1 | 69 | 0.59 (0.21-1.61) | 0.302 | 14 | 0.91 (0.32-2.55) | 0.850 | |
| 2 | 47 | 0.63 (0.21-1.88) | 0.406 | 6 | 0.72 (0.22-2.38) | 0.593 | |
| >2 | 46 | 0.70 (0.24-2.01) | 0.505 | 10 | 1.13 (0.38-3.33) | 0.823 | |
| Previous abdominal surgery | |||||||
| No | 139 | 23 | 1.00 | 28 | 1.00 | ||
| Yes | 49 | 8 | 0.94 (0.42-2.09) | 0.871 | 7 | 0.7 (0.3-1.62) | 0.408 |
| FIGO stage | |||||||
| IA | 83 | 7 | 1.00 | 10 | 1.00 | ||
| IB | 69 | 11 | 2.02 (0.78-5.21) | 0.147 | 14 | 1.81 (0.79-4.11) | 0.158 |
| II | 10 | 4 | 5.28 (1.54-18.06) | 0.008 | 3 | 2.21 (0.61-8.07) | 0.229 |
| IIIA | 5 | 3 | 13.37 (3.45-51.85) | <0.0001 | 1 | 2.3 (0.29-18.11) | 0.431 |
| IIIB | 2 | 2 | 29.06 (5.68-148.82) | <0.0001 | 1 | 7.67 (0.97-60.65) | 0.053 |
| IIIC | 17 | 3 | 2.22 (0.57-8.59) | 0.248 | 5 | 2.52 (0.86-7.4) | 0.092 |
| IVB | 2 | 1 | 11.5 (1.38-95.54) | 0.024 | 1 | 13.53 (1.63-112.51) | 0.016 |
| Histotype | |||||||
| Endometrioid | 161 | 25 | 1.00 | 22 | 1.00 | ||
| NEEC | 27 | 6 | 1.54 (0.63-3.75) | 0.343 | 13 | 3.56 (1.78-7.11) | <0.0001 |
| Grading | |||||||
| 1 | 32 | 6 | 1.00 | 3 | 1.00 | ||
| 2 | 97 | 10 | 0.48 (0.17-1.32) | 0.156 | 12 | 1.12 (0.32-3.99) | 0.859 |
| 3 | 59 | 15 | 1.34 (0.52-3.45) | 0.547 | 20 | 3.08 (0.91-10.48) | 0.071 |
| Lymph node metastasis | |||||||
| No | 168 | 27 | 1.00 | 31 | 1.00 | ||
| Yes | 20 | 4 | 1.28 (0.45-3.67) | 0.643 | 4 | 1.18 (0.42-3.37) | 0.754 |
| Surgical approach | |||||||
| LPS | 94 | 16 | 1.00 | 22 | 1.00 | ||
| RS | 94 | 15 | 0.95 (0.47-1.93) | 0.890 | 13 | 0.86 (0.42-1.77) | 0.683 |
| Adjuvant therapy | |||||||
| No | 81 | 9 | 1.00 | 11 | 1.00 | ||
| Yes | 107 | 22 | 2 (0.92-4.35) | 0.080 | 24 | 1.79 (0.87-3.65) | 0.111 |
Bold font highlights statistically significant difference. HR, Hazard Ratio; CI, Confidence Interval; BMI, Body Mass Index; NEEC, Not endometrioid endometrial cancer; LPS, Laparoscopic Surgery; RS, Robotic Surgery.